Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells. (April 2015)

• Record Type: Journal Article
• Authors: Peschl, Patrick; Reindl, Markus; Schanda, Kathrin; Sospedra, Mireia; Martin, Roland; Lutterotti, Andreas
• Is Part Of: Multiple sclerosis. Volume 21:Number 5(2015)
• Page Start: 651
• Page End: 655
• Publication Date: 2015-04
• Subjects: Multiple sclerosis -- tolerance -- antigen-coupled cell -- antibody -- myelin; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/1352458514549405
• Languages: English
• ISSNs: 1352-4585

Abstract

We have recently demonstrated the safety and tolerability of a novel therapeutic regimen employing autologous blood cells chemically coupled with seven myelin peptides to induce antigen-specific tolerance in MS (ETIMS study). The aim of the current study was an extended safety analysis to assess the effect of the ETIMS approach on antibodies to common autoantigens, the myelin peptides used and common recall antigens. None of the patients showed induction of autoantibody responses. One patient had a measurable myelin peptide-specific response at baseline, which was reduced after treatment. Total immunoglobulins and recall antibody responses showed no significant change.